Urea Cycle Disorders Treatment Market size was valued at US$ 1,188.9 million in 2020 and is expected to exhibit a CAGR of 3.5% between 2022 and 20278

The global urea cycle disorders treatment market was valued at US$ 1,188.9 million in 2020 and is expected to exhibit a CAGR of 3.5 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Urea cycle disorder (UCD) is an inherited/hereditary disease that affects how the body removes the waste that is made from breaking down protein. There are different types of urea cycle disorders. The most common type of UCD is ornithine Transcarbamylase Deficiency (OTC). The urea cycle disorders (UCD) treatment is a lifelong process aimed at managing symptoms and doesn’t cure the disorder. Urea cycle disorder is triggered by an alteration in genes, which causes insufficiency of any of the six vital enzymes essential for the urea cycle. The diagnosis of UCD is done with the urine and blood test. The urea cycle disorders treatment include dietary management to limit ammonia production. Moreover, liver transplantation can be an effective treatment for UCD for the proper functioning of urea cycle.

LIMITED TIME OFFER – Hurry Up!!!

Buy Now To Avail Flat 30% Off

Purchase This Premium Report With Discounted Rate @ https://www.coherentmarketinsights.com/insight/buy-now/4441

Competitive Landscape:

Major players operating in the global urea cycle disorders treatment market are DANONE S.A., NESTLÉ S.A., Abbott Laboratories, Selecta Biosciences, Inc., Orpharma Pty Ltd., Recordati Rare Diseases Inc., Aeglea BioTherapeutics, Bausch Health Companies, Acer Therapeutics, Lucane Pharma SA, Mead Johnson & Company, LLC, Ultragenyx Pharmaceutical Inc., and Arcturus Therapeutics Holdings Inc., among others.

Key Market Drivers:

High prevalence of UCD is expected to boost the growth of the urea cycle disorders treatment market during the forecast period. For instance, according to the American Association for Clinical Chemistry’s (AACC’s) 2019 report, the incidence of UCDs in the U.S. is estimated to be 1 in 8200 births. The calculated overall average birth prevalence of UCDs is approximated to be 1 in 35,000, with two-thirds having symptoms in the neonatal period.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4441

Moreover, increasing demand for safe-effective urea cycle disorders treatment and increasing initiatives by market players for the development safe and effective treatment are expected to aid in the growth of the urea cycle disorders treatment market. For instance, in October 2021, Boehringer Ingelheim and Thoeris signed a collaboration and license agreement to investigate new treatments for patients suffering from urea cycle disorders (UCDs).

COVID-19 Impact Analysis:

The outbreak of COVID-19 and the consequent lockdown in various countries worldwide has affected the financial status of major players active in the urea cycle disorders treatment market. The pandemic has severely impacted the market in various aspects, such as the production, research and development, and supply of medications. Moreover, the outbreak of COVID-19 has affected the growth of several pharma companies due to the safety measures enforced by the governments of several countries to curb the spread of the virus. This in turn is expected to hinder growth of the market.

Key Takeaways:

• The urea cycle disorders treatment market is expected to exhibit a CAGR of 3.5 % over the forecast period owing to the increasing number of pipeline products. For instance, in October 2020, Versantis AG announced that the US Food and Drug Administration (FDA) has granted a rare pediatric disease designation (RPDD) to its lead product candidate VS-01, an ammonia clearance enhancer, for the treatment of urea cycle disorders (UCDs).
• Among regions, North America and Europe are expected to witness substantial growth in the urea cycle disorders treatment market owing to the increasing prevalence of urea cycle disorders in the region. For instance, in March 2018, Swedish Orphan Biovitrum AB (Sobi) announces that the company has gained reimbursement for Ravicti, a new therapy option for the treatment of patients with urea cycle disorders (UCDs) in several EU member states and EEA-countries. Sweden, Denmark, Austria and Germany are the first countries to launch, followed by UK, Spain, and the Netherlands.

Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4441

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snapshot, By Treatment Type
     • Market Snapshot, By Enzyme Deficiency Type
     • Market Snapshot, By Route of Administration
     • Market Snapshot, By Distribution Channel
     • Market Snapshot, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Drivers
   • Restraints
   • Opportunities
   • Impact Analysis
   • Key Developments
   • Treatment Approaches
   • Novel Therapies Under Development for the Treatment of UCD
   • Mergers, Collaborations, Acquisitions & Agreements
   • Pipeline Analysis
   • Regulatory Scenario
   • PEST Analysis
   • Product Approvals
   • Market Trends
   • Epidemiology
   • Therapeutics Overview
   • Brand Analysis
   • Reimbursement Scenario
   • Prescription Overview
4. Global Urea Cycle Disorders Treatment Market, Impact of COVID-19 Pandemic
   • COVID-19 Impact on Overall Healthcare Sector
   • COVID-19 Epidemiology
   • Impact of COVID-19 Impact on Supply Chain
   • Covid-19 Impact on Clinical Trials and Drug Development
5. Global Urea Cycle Disorders Treatment Market, By Treatment Type, 2016-2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
       • Amino Acid Supplements
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Sodium Phenylbutyrate
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Glycerol Phenylbutyrate
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Sodium Benzoate
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Others (Low Protein Diet, Carglumic acid, etc.)
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
6. Global Urea Cycle Disorders Treatment  Market, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
   • Introduction
   • Market Share Analysis, 2020 and 2027 (%)
   • Y-o-Y Growth Analysis, 2017–2027
   • Segment Trends
     • • OTC – Ornithine Transcarbamylase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • AS – Argininosuccinate Synthetase (citrullinemia)
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • AG – Arginase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • AL – Argininosuccinate Lyase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • CPS1 – Carbamoyl Phosphate Synthase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • NAGS – N-acetylglutamate Synthase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
7. Global Urea Cycle Disorders Treatment Market, By Route of Administration, 2016–2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
       • Oral
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Injectable
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
8. Global Urea Cycle Disorders Treatment Market, By Distribution Channel, 2016–2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
       • Hospital Pharmacies
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Retail Pharmacies
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Online Pharmacies
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
9. Global Urea Cycle Disorders Treatment Market, By Region, 2016–2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, By Country, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, For Countries, 2017–2027
   • North America
     • Introduction
     • Market Size and Forecast, By Treatment Type, 2016–2027 (US$ Mn)
     • Market Size and Forecast, By Enzyme Deficiency Type, 2016–2027 (US$ Mn)
     • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
     • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
     • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
       • U.S.
       • Canada
   • Latin America
     • • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Europe
     • Germany
     • U.K.
     • France
     • Italy
     • Spain
     • Russia
     • Rest of Europe
   • Asia Pacific
     • China
     • India
     • Japan
     • Australia
     • South Korea
     • ASEAN
     • Rest of Asia Pacific
   • Middle East
     • GCC
     • Israel
     • Rest of Middle East
   • Africa
     • South Africa
     • Central Africa
     • North Africa